CO2023013486A2 - Derivados de pirazolopiridina y sus usos - Google Patents
Derivados de pirazolopiridina y sus usosInfo
- Publication number
- CO2023013486A2 CO2023013486A2 CONC2023/0013486A CO2023013486A CO2023013486A2 CO 2023013486 A2 CO2023013486 A2 CO 2023013486A2 CO 2023013486 A CO2023013486 A CO 2023013486A CO 2023013486 A2 CO2023013486 A2 CO 2023013486A2
- Authority
- CO
- Colombia
- Prior art keywords
- hemoglobinopathies
- beta
- expression
- pyrazolopyridine derivatives
- wiz
- Prior art date
Links
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 102100020716 Protein Wiz Human genes 0.000 abstract 2
- 101710186935 Protein Wiz Proteins 0.000 abstract 2
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 2
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a compuestos de Fórmula (I) y composiciones farmacéuticas y su uso en la reducción de los niveles de expresión de los Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ), o en la inducción de la expresión de la hemoglobina fetal (HbF), y en el tratamiento de trastornos de la sangre hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, beta–hemoglobinopatías), tales como la enfermedad de células falciformes y beta–talasemia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161139P | 2021-03-15 | 2021-03-15 | |
| US202163164130P | 2021-03-22 | 2021-03-22 | |
| PCT/IB2022/052281 WO2022195454A1 (en) | 2021-03-15 | 2022-03-14 | Pyrazolopyridine derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023013486A2 true CO2023013486A2 (es) | 2023-11-10 |
Family
ID=80819999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0013486A CO2023013486A2 (es) | 2021-03-15 | 2023-10-12 | Derivados de pirazolopiridina y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11787785B2 (es) |
| EP (1) | EP4308562A1 (es) |
| JP (1) | JP2024509981A (es) |
| KR (1) | KR20230156766A (es) |
| AU (1) | AU2022239950A1 (es) |
| BR (1) | BR112023018542A2 (es) |
| CA (1) | CA3208951A1 (es) |
| CL (1) | CL2023002726A1 (es) |
| CO (1) | CO2023013486A2 (es) |
| CR (1) | CR20230486A (es) |
| DO (1) | DOP2023000188A (es) |
| EC (1) | ECSP23076800A (es) |
| IL (1) | IL305931A (es) |
| MX (1) | MX2023010827A (es) |
| TW (1) | TW202304900A (es) |
| UY (1) | UY39671A (es) |
| WO (1) | WO2022195454A1 (es) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| AU2009241137B2 (en) | 2008-04-28 | 2013-10-03 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylic acid amide derivative |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| JP2013519675A (ja) | 2010-02-11 | 2013-05-30 | セルジーン コーポレイション | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| CN104619709B (zh) | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| JP2020009513A (ja) * | 2018-07-10 | 2020-01-16 | キオクシア株式会社 | メモリシステム |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| UY38986A (es) | 2019-12-18 | 2021-07-30 | Novartis Ag | Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas |
| CN115362145A (zh) | 2020-02-04 | 2022-11-18 | 斯汀格瑞治疗股份有限公司 | 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)抑制剂及其使用方法 |
| JP2023514188A (ja) | 2020-02-09 | 2023-04-05 | ニューウェーブ・ファーマスーティカル・インコーポレイテッド | 抗がん剤としてのキヌクリジノン系化合物の応用 |
-
2022
- 2022-03-11 UY UY0001039671A patent/UY39671A/es unknown
- 2022-03-14 JP JP2023556474A patent/JP2024509981A/ja active Pending
- 2022-03-14 BR BR112023018542A patent/BR112023018542A2/pt unknown
- 2022-03-14 CR CR20230486A patent/CR20230486A/es unknown
- 2022-03-14 IL IL305931A patent/IL305931A/en unknown
- 2022-03-14 TW TW111109165A patent/TW202304900A/zh unknown
- 2022-03-14 KR KR1020237034868A patent/KR20230156766A/ko active Search and Examination
- 2022-03-14 AU AU2022239950A patent/AU2022239950A1/en active Pending
- 2022-03-14 EP EP22711643.1A patent/EP4308562A1/en active Pending
- 2022-03-14 US US17/693,759 patent/US11787785B2/en active Active
- 2022-03-14 CA CA3208951A patent/CA3208951A1/en active Pending
- 2022-03-14 WO PCT/IB2022/052281 patent/WO2022195454A1/en active Application Filing
- 2022-03-14 MX MX2023010827A patent/MX2023010827A/es unknown
-
2023
- 2023-09-01 US US18/460,428 patent/US20240158374A1/en active Pending
- 2023-09-13 DO DO2023000188A patent/DOP2023000188A/es unknown
- 2023-09-13 CL CL2023002726A patent/CL2023002726A1/es unknown
- 2023-10-12 CO CONC2023/0013486A patent/CO2023013486A2/es unknown
- 2023-10-12 EC ECSENADI202376800A patent/ECSP23076800A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304900A (zh) | 2023-02-01 |
| US11787785B2 (en) | 2023-10-17 |
| CA3208951A1 (en) | 2022-09-22 |
| MX2023010827A (es) | 2023-09-28 |
| WO2022195454A1 (en) | 2022-09-22 |
| UY39671A (es) | 2022-10-31 |
| US20240158374A1 (en) | 2024-05-16 |
| KR20230156766A (ko) | 2023-11-14 |
| EP4308562A1 (en) | 2024-01-24 |
| ECSP23076800A (es) | 2023-11-30 |
| IL305931A (en) | 2023-11-01 |
| AU2022239950A1 (en) | 2023-08-31 |
| DOP2023000188A (es) | 2023-11-15 |
| CL2023002726A1 (es) | 2024-04-01 |
| US20230108325A1 (en) | 2023-04-06 |
| JP2024509981A (ja) | 2024-03-05 |
| BR112023018542A2 (pt) | 2023-10-10 |
| CR20230486A (es) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| BR112015011158A8 (pt) | triazolopirazina, seu uso e preparação farmacêutica | |
| UY27834A1 (es) | Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. | |
| CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| UY30481A1 (es) | Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos. | |
| UY28732A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparación y su uso como medicamentos. | |
| UY30282A1 (es) | Compuestos quimicos | |
| ECSP24000004A (es) | Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| BR112014013140A2 (pt) | cosmética de prótese | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| AR112353A1 (es) | Compuesto de insulina acilada | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| CY1115734T1 (el) | Συνθεσεις benzenesulfonamide, μεθοδος συνθεσης τους, και χρηση αυτων στην ιατρικη | |
| BRPI0514030A (pt) | derivados de ácido hidroxámico substituìdo por arilssulfonamida, como inibidores de metaloproteinases de matrizes | |
| ECSP22087958A (es) | Compuestos de insulina acilada de acción temporal prolongada | |
| UY28210A1 (es) | Derivados de ácido acético sustituido con cicloalquilmetoxi, procedimientos para su preparacion y su uso como farmacos. | |
| AR037766A1 (es) | Compuestos triaromaticos analogos de la vitamina d, su utilizacion, composiciones farmaceuticas y cosmeticas que los comprenden y utilizacion cosmetica de dichas composiciones cosmeticas | |
| CO2023013486A2 (es) | Derivados de pirazolopiridina y sus usos | |
| JP2013525342A5 (es) | ||
| CY1123360T1 (el) | Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος | |
| ES2703530T3 (es) | Composición cicatrizante y utilización | |
| UY29550A1 (es) | Derivados de (sulfamoil-alquil)-amida de ácido heteroaril-carboxílico como inhibidores del factor xa | |
| ECSP055984A (es) | Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas |